Artificial Intelligence for Pharmacovigilance Processing – What is Possible Today
Drug side effect reporting (also called pharmacovigilance) is a massive undertaking for biotech and pharmaceutical companies as well as for Regulatory agencies. Lately, with global COVID-19 vaccine programs, further impact on side effect volumes have been experienced, making it a costly and time-consuming process. Using NLP, and other automation techniques, is a promising way to cope more efficiently with work-loads, but here a number of challenges are to be tackled. In this session, we will go through learnings from a previous drug safety-focused “AI Data Analyzer” public-private (Innobooster) initiative as well as the ongoing NLP implementation using Spark NLP with a major Regulatory agency, with the aim of suggesting how and where to get the most value of machine-derived data in the actual processing of side effect reports.
CEO at Insife
Executive leader with 10 years of experience within the pharma industry and another 10+ years in consulting. Martin is an experienced manager and strategist, with understanding across the pharma business value chain, and an expert on Pharmacovigilance. His current role is CEO of Insife, a global technology and consulting company. In this capacity, digital transformation is central to Martin’s engagements with Industry and Regulatory
Agencies. In his previous role, he headed the pvtech global industry pharmacovigilance technology network with more than half of top
100 pharma participating.
Data Scientist Insife
Amit Arora is a Data Scientist working with Insife and have 3 years of experience in data science field. He has completed his Master’s degree in Data science and Analytics from University of London. He has strong background in Mathematical, Statistical, Machine Learning and Natural Language Processing. He has worked in different domains including Insurance domain, Travel domain and Pharmacovigilance domain. Recently he has passed the SparkNLP Data Scientist Healthcare certification. Agencies. In his previous role, he headed the pvtech global industry pharmacovigilance technology network with more than half of top 100 pharma participating.